- Home
- CCBG vs PHAT Comparison
CCBG vs PHAT Comparison
Compare CCBG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | PHAT |
|---|---|---|
| Founded | 1895 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.1M | 759.7M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CCBG | PHAT |
|---|---|---|
| Price | $51.12 | $9.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $50.00 | $19.83 |
| AVG Volume (30 Days) | 50.3K | ★ 1.2M |
| Earning Date | 04-20-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | 15.38 | ★ 42.72 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $6.25 | $93.04 |
| Revenue Next Year | $3.17 | $58.91 |
| P/E Ratio | $55.41 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $38.27 | $8.21 |
| 52 Week High | $53.60 | $18.31 |
Technical Indicators
Market Signals| Indicator | CCBG | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 47.69 |
| Support Level | $50.98 | $8.46 |
| Resistance Level | $51.04 | $9.75 |
| Average True Range (ATR) | 0.93 | 0.49 |
| MACD | -0.21 | 0.13 |
| Stochastic Oscillator | 37.57 | 60.97 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.